# Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Source: https://onco.cc/trials/nct06792253/  
OnCo record `nct06792253` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Ifupinostat in diffuse large B-cell lymphoma, now recruiting.

## Summary

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma is a phase 3 interventional study registered as NCT06792253, led by BeBetter Med, and recruiting on the registry. Official title: Phase Ⅲ Clinical Trial Comparing BEBT-908 Combined With Rituximab (R) to Standard of Care for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Planned enrolment is 416 participants (estimated). The study started in 2025-01-06 and primary completion is expected in 2028-12-31. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06792253
- Phase: 3
- Setting: Phase Ⅲ Clinical Trial Comparing BEBT-908 Combined With Rituximab (R) to Standard of Care for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Sponsor: BeBetter Med
- Enrolled: 416

## Sources

- ClinicalTrials.gov NCT06792253: https://clinicaltrials.gov/study/NCT06792253

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Ifupinostat](https://onco.cc/drugs/ifupinostat/)
- companies: [BeBetter Med](https://onco.cc/companies/bebetter-med/)

---
JSON: https://onco.cc/api/v1/entities/nct06792253.json